HUNAN DAJIAWEIKANG PHARMACEUTICAL INDUSTRY CO.,LTD Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Stock
Equities
301126
CNE1000054V3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.48 CNY | +1.85% |
|
+2.95% | -19.57% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.29B 456M 622M | Sales 2023 | 3.9B 541M 737M | Capitalization | 2.69B 373M 508M |
|---|---|---|---|---|---|
| Net income 2022 | 51M 7.06M 9.63M | Net income 2023 | 34M 4.71M 6.42M | EV / Sales 2022 | 1.23 x |
| Net Debt 2022 | 967M 134M 183M | Net Debt 2023 | 1.92B 267M 363M | EV / Sales 2023 | 1.18 x |
| P/E ratio 2022 |
59.6
x | P/E ratio 2023 |
76.6
x | Employees | 3,461 |
| Yield 2022 |
0.19% | Yield 2023 |
0.31% | Free-Float | 37.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.85% | ||
| 1 week | +2.95% | ||
| Current month | +9.85% | ||
| 1 month | +14.16% | ||
| 3 months | +38.81% | ||
| 6 months | -24.82% | ||
| Current year | -19.57% |
1 week
10.11
12.35
1 month
7.5912.35
Current year
6.6114.39
1 year
6.6116.85
3 years
6.6136.84
5 years
6.6136.84
10 years
6.6136.84
| Managers | Title | Age | Since |
|---|---|---|---|
Sheng Li Hu
CEO | Chief Executive Officer | 50 | 17-04-15 |
Juan Tang
CHM | Chairman | 53 | 02-06-30 |
Yi Qing Wang
CHM | Chairman | 59 | 02-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Tang
BRD | Director/Board Member | 51 | 19-11-13 |
Shu Ping Liu
BRD | Director/Board Member | 54 | 20-09-09 |
Yi Qing Wang
CHM | Chairman | 59 | 02-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 10.48 | +1.85% | 12,835,470 |
| 24-05-13 | 10.29 | -7.05% | 15,295,670 |
| 24-05-10 | 11.07 | -10.36% | 28,471,750 |
| 24-05-09 | 12.35 | +20.02% | 23,631,870 |
| 24-05-08 | 10.29 | +1.08% | 5,913,674 |
End-of-day quote Shenzhen S.E., May 13, 2024
More quotes
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
Sector
Pharmaceuticals
Calendar
2024-07-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.57% | 299M | |
| +19.14% | 71.7B | |
| -3.34% | 23.73B | |
| +10.27% | 9.01B | |
| +12.67% | 8.72B | |
| -17.41% | 8.29B | |
| +16.12% | 5B | |
| +21.40% | 4.48B | |
| -1.41% | 4.08B | |
| -2.13% | 3.92B |
- Stock Market
- Equities
- 301126 Stock